AOAnja Weinreich Olsen

Anja Weinreich Olsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anja Weinreich Olsen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice

    by Anja W. Olsen, Ida Rosenkrands, Christina S. Jacobsen, Hannah M. Cheeseman, Max P. Kristiansen, Jes Dietrich, Robin J. Shattock, Frank Follmann

    The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.


  • Open Access

    Immune signature of the Chlamydia vaccine CTH522/CAF®01 translates from mouse to human and induces durable protection

    by Anja Olsen, Ida Rosenkrands, Christina Jacobsen, Hannah Cheeseman, Max Kristiansen, Jes Dietrich, Robin Shattock, Frank Follmann

    The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here we report the first comparative immunological characterization of CTH522/CAF®01 in mice and humans. We find a range of immune signatures that translate from mouse to humans, including a Th1/Th17 cytokine profile and antibody functionality. Interestingly, we identified vaccine-induced T cell epitopes, conserved among serovars and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.

  • Open Access

    Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

    by Anja Weinreich Olsen, Ida Rosenkrands, Martin J. Holland, Peter Andersen, Frank Follmann


  • Open Access

    Adherence to the EAT-Lancet diet and risk of incident type 2 diabetes: the Danish Diet, Cancer and Health cohort

    by Fie Langmann, Daniel B. Ibsen, Anne Tjoenneland, Anja Olsen, Kim Overvad, Christina C. Dahm

    Objective: In 2019 the EAT-Lancet Commission proposed a dietary pattern, defined to be globally environmentally sustainable, but untested directly in population studies with regards to health. We investigated adherence to the EAT-Lancet diet and risk of incident type 2 diabetes in a Danish setting. Research design and methods: In total, 54,232 participants aged 50-64 years at inclusion (1993-1997) with no previous cancer or diabetes diagnoses were included. Dietary data were collected using a validated 192-item food frequency questionnaire, and scored 0 (non-adherence) or 1 (adherence) point for each of the 14 dietary components of the EAT-Lancet diet (range 0-14 points). Incident type 2 diabetes cases were identified using the Danish National Diabetes Register. Hazard ratios and 95% confidence intervals (CI) were estimated using multivariable-adjusted Cox proportional hazards models. Results: During follow-up (median 15 years), 7130 participants developed type 2 diabetes. There was a 22% (95% CI: 14%; 29%) lower risk of type 2 diabetes among those with the greatest adherence to the EAT-Lancet diet (11-14 points) compared to those with the lowest adherence (0-7 points). After further adjusting for potential mediators, the corresponding risk was 17% (95% CI: 8%; 24%) lower. Conclusion: Adherence to the EAT-Lancet diet was associated with a lower risk of developing type 2 diabetes in a middle-aged Danish population.

  • Open Access

    A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

    by Anja Weinreich Olsen, Ida Rosenkrands, Martin J. Holland, Peter Andersen, Frank Follmann

    Ocular and urogenital infections withChlamydia trachomatis (C.t.) are caused by a range of different serovars. The firstC.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1Aand extVD1J, and repeated this region four times. The extVD1A*4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1A*4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.


  • Open Access

    Genital tract lesions in sexually mature Göttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D

    by Karin Erneholm, Emma Lorenzen, Sarah Bøje, Anja Weinreich Olsen, Peter Andersen, Joseph P. Cassidy, Frank Follmann, Henrik E. Jensen, Jørgen S. Agerholm

    Chlamydia is one of the most common sexually transmitted diseases in humans worldwide, causing chronic lesions in the reproductive tract. Due to its often asymptomatic course, there is limited knowledge about the initial changes in the genital tract following infection. This study employs a novel sexually mature minipig model to investigate the initial histopathological changes following vaginal infection with Chlamydia trachomatis serovar D. A vaginal inoculation resulted in an infection primarily affecting the lower genital tract. The histopathological changes were characterized by a subepithelial inflammation consisting of neutrophils and mononuclear cells, followed by an increase in the number of plasma cells within the sub-epithelial stroma of the vagina. Detection of Chlamydia was associated with expression of cyclooxygenase-2 and interleukin-8 by superficial epithelial cells. The infection was self-limiting, with a duration of 7 days. Neutrophils, plasma cells and IL-8 have been linked with Chlamydia genital infection of unknown duration in human patients. In this study, we observe a similar pattern of local immune response/inflammation following experimental inoculation suggesting this porcine model shows promise as a model for translational chlamydia research.


  • Screening and Characterization of Linear B-Cell Epitopes by Biotinylated Peptide Libraries

    by Ida Rosenkrands, Anja Olsen

    Identification of B-cell epitopes is important for the use of antibodies as therapeutic agents, the design of epitope-based vaccines against infectious diseases, and immunological assays based on peptide antibodies. A large number of methods are available for epitope mapping, but many of them require specialized laboratories and are expensive. In this chapter, we describe a high-throughput approach for epitope mapping of peptide antibodies by use of a library of soluble, overlapping, biotinylated peptides. As example, we present characterization of monoclonal and polyclonal antibodies specific for peptides of Mycobacterium tuberculosis acyl carrier protein AcpM and the Chlamydia trachomatis chaperone Ct043 by ELISA.


  • Open Access

    Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared with a Primary Intranasal Infection in a Mouse Genital Challenge Model

    by Anja Weinreich Olsen, Michael Theisen, Dennis Christensen, Frank Follmann, Peter Andersen

    The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been identified as human B and/or T cell targets during a chlamydial infection in humans. Here we compare the protective effector mechanism promoted by a fusion protein composed of CT521 and CT443 (CTH1) with a primary intranasal Chlamydia muridarum infection known to provide high levels of protection against a genital chlamydial challenge. The fusion protein CTH1, adjuvanted with a strong Th1 inducing cationic adjuvant (CAF01), significantly reduced the bacterial shedding compared to a control group in both a C. trachomatis Serovar D and C. muridarum challenge model. The CTH1/CAF01 vaccine was found to induce polyfunctional T cells consisting of TNFα/IL-2 and TNFα/IL-2/IFN-γ positive cells and high titers of CTH1 specific IgG2a and IgG1. By depletion experiments the protection in the C. muridarum challenge model was demonstrated to be mediated solely by CD4+ T cells. In comparison, an intranasal infection with C. muridarum induced a T cell response that consisted predominantly of TNFα/IFN-γ co-expressing effector CD4+ T cells and an antibody response consisting of C. muridarum specific IgG1, IgG2a but also IgA. This response was associated with a high level of protection against challenge—a protection that was only partially dependent on CD4+ T cells. Furthermore, whereas the antibody response induced by intranasal infection was strongly reactive against the native antigens displayed in the chlamydial elementary body, only low levels of antibodies against this preparation were found after CTH1/CAF01 immunization. Our data demonstrate that CTH1 vaccination promotes a CD4+ T cell dependent protective response but compared with intranasal C. muridarum infection lacks a CD4 independent protective mechanism for complete protection.


  • Open Access

    Identification of CT521 as a Frequent Target of Th1 Cells in Patients with UrogenitalChlamydia trachomatisInfection

    by Anja Weinreich Olsen, Frank Follmann, Klaus Jensen, Peter Højrup, Robert Leah, Hanne Sørensen, Steen Hoffmann, Peter Andersen, Michael Theisen

    BackgroundThe human immune response to a Chlamydia trachomatis serovar D lysate was investigated in patients with urogenital C. trachomatis infection